BioMarin Pharmaceutical Inc. (LON:0HNC)
London · Delayed Price · Currency is GBP · Price in USD 52.84
+1.03 (1.99%)
At close: Oct 31, 2025
BioMarin Pharmaceutical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 520.42 | 426.86 | 167.65 | 141.56 | -64.08 | 854.03 | Upgrade |
Depreciation & Amortization | 82.73 | 96.43 | 104.39 | 101.97 | 108.04 | 105.17 | Upgrade |
Loss (Gain) From Sale of Assets | - | -10 | - | -108 | - | -52.82 | Upgrade |
Asset Writedown & Restructuring Costs | 223.93 | 19.89 | 38.61 | - | - | - | Upgrade |
Loss (Gain) From Sale of Investments | -5.42 | -8.35 | -9.23 | 3.04 | 5.16 | 0.57 | Upgrade |
Stock-Based Compensation | 186.42 | 201.57 | 207.1 | 196.31 | 197.26 | 189.71 | Upgrade |
Other Operating Activities | 118.67 | 62.84 | -12.71 | -62.6 | -7.88 | -786.36 | Upgrade |
Change in Accounts Receivable | -34.83 | -57.91 | -190.44 | -82.03 | 65.57 | -59.04 | Upgrade |
Change in Inventory | -133.07 | -63.53 | -157.06 | -68.26 | -35.06 | -61.15 | Upgrade |
Change in Accounts Payable | 19.22 | -32.24 | 68.85 | 59.02 | 15.69 | -87.03 | Upgrade |
Change in Other Net Operating Assets | -64.08 | -62.72 | -57.9 | -5.1 | 19.83 | -17.72 | Upgrade |
Operating Cash Flow | 913.98 | 572.84 | 159.26 | 175.9 | 304.54 | 85.37 | Upgrade |
Operating Cash Flow Growth | 120.40% | 259.69% | -9.46% | -42.24% | 256.75% | 76.88% | Upgrade |
Capital Expenditures | -81.85 | -85.42 | -96.69 | -120.96 | -95.58 | -114.31 | Upgrade |
Cash Acquisitions | -285.19 | - | - | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | -6.34 | -1.99 | -10.92 | 92.74 | -23.65 | 43.95 | Upgrade |
Investment in Securities | 77.99 | 222.77 | -3.63 | 8.19 | -246.09 | 26.17 | Upgrade |
Other Investing Activities | - | 1.14 | - | - | -0.99 | -9.43 | Upgrade |
Investing Cash Flow | -295.39 | 136.49 | -111.24 | -20.03 | -366.31 | -53.62 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 585.75 | Upgrade |
Long-Term Debt Repaid | - | -494.99 | - | - | -3.04 | -381.91 | Upgrade |
Net Debt Issued (Repaid) | - | -494.99 | - | - | -3.04 | 203.84 | Upgrade |
Issuance of Common Stock | 15.58 | 49.28 | 69.35 | 69.33 | 49.19 | 71.91 | Upgrade |
Repurchase of Common Stock | -58.17 | -77.56 | -76.32 | -54.28 | -45.81 | -94.64 | Upgrade |
Other Financing Activities | -0.09 | -3.18 | -11.76 | -33.7 | -0.4 | - | Upgrade |
Financing Cash Flow | -42.69 | -526.45 | -18.73 | -18.65 | -0.05 | 181.12 | Upgrade |
Foreign Exchange Rate Adjustments | -1.24 | 4.83 | 1.31 | 0.03 | -0.06 | -1.15 | Upgrade |
Net Cash Flow | 574.66 | 187.72 | 30.6 | 137.26 | -61.88 | 211.71 | Upgrade |
Free Cash Flow | 832.13 | 487.42 | 62.57 | 54.94 | 208.96 | -28.95 | Upgrade |
Free Cash Flow Growth | 160.13% | 679.02% | 13.88% | -73.71% | - | - | Upgrade |
Free Cash Flow Margin | 26.90% | 17.08% | 2.59% | 2.62% | 11.32% | -1.56% | Upgrade |
Free Cash Flow Per Share | 4.23 | 2.48 | 0.33 | 0.29 | 1.14 | -0.15 | Upgrade |
Cash Interest Paid | 7.28 | 10.36 | 10.3 | 10.28 | 10.4 | 12.18 | Upgrade |
Cash Income Tax Paid | 91.39 | 57.27 | 73.31 | 54.37 | 18.15 | 8.98 | Upgrade |
Levered Free Cash Flow | 451.55 | 271.54 | -17.35 | 137.32 | 201.61 | -18.77 | Upgrade |
Unlevered Free Cash Flow | 458.24 | 279.46 | -6.52 | 147.3 | 211.19 | -0.45 | Upgrade |
Change in Working Capital | -212.76 | -216.4 | -336.54 | -96.38 | 66.03 | -224.94 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.